Despite this, small-molecule inhibitors targeting SOS1 have shown limited efficacy in clinical trials for KRAS-mutant cancers, and their potential as a therapeutic approach for chronic myeloid leukemia (CML) remains largely unexplored. This evidence concerns the gene KRAS and chronic myelogenous leukemia, BCR-ABL1 positive.